JP5826456B2 - コーティングされていない分離したユニットおよび延長放出マトリクスを含む制御放出配合物 - Google Patents
コーティングされていない分離したユニットおよび延長放出マトリクスを含む制御放出配合物 Download PDFInfo
- Publication number
- JP5826456B2 JP5826456B2 JP2009506867A JP2009506867A JP5826456B2 JP 5826456 B2 JP5826456 B2 JP 5826456B2 JP 2009506867 A JP2009506867 A JP 2009506867A JP 2009506867 A JP2009506867 A JP 2009506867A JP 5826456 B2 JP5826456 B2 JP 5826456B2
- Authority
- JP
- Japan
- Prior art keywords
- unit
- release
- galantamine
- units
- formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Description
(i)単位投与量の活性医薬成分またはその医薬的に受容可能な塩;
(ii)1種以上の延長放出剤;および任意選択的に、
(iii)1種以上の医薬的に受容可能な賦形剤
を含み、単位投与量の合計が活性医薬成分の医薬的に有効な量を構成することを特徴とする、制御放出配合物が提供される。
(i)医薬的に有効な量の活性医薬成分;
(ii)1種以上の延長放出剤;および
(iii)崩壊剤
を含み、かつ任意選択的に1種以上の医薬的に受容可能な賦形剤を含むことを特徴とする制御放出組成物が提供される。
(1)各ユニットが、
(i)単位投与量の活性医薬成分またはその医薬的に受容可能な塩;
(ii)1種以上の延長放出剤;および任意選択的に
(iii)1種以上の医薬的に受容可能な賦形剤
を含む別個の分離したユニットを調製する工程;および
(2)単回投与における投与を可能にするように1つ以上の前記ユニットを物理的に並置する工程
を含む、方法が提供される。
成分 mg/タブレット
ガランタミン HBr 10.256
(8mgのガランタミンに相当する)
Povidone K90 4.0
PVA & PVP 46.744
硬化植物油 28.0
ステアリン酸マグネシウム 1.0
成分 mg/タブレット
ガランタミン HBr 10.256
(8mgのガランタミンに相当する)
Povidone K90 2.0
PVA & PVP 23.244
硬化植物油 14.0
ステアリン酸マグネシウム 0.5
成分 mg/タブレット
ガランタミン HBr 10.256
(8mgのガランタミンに相当する)
Povidone K90 2.0
PVA & PVP 26.244
硬化植物油 11.0
ステアリン酸マグネシウム 0.5
小型タブレット
成分 mg/タブレット
ガランタミン HBr 5.128
(4mgのガランタミンに相当する)
ラクトース(噴霧乾燥物) 21.122
Hypromellose K100MCR 18.0
無水コロイドシリカ 0.25
ステアリン酸マグネシウム 0.5
コーティング
Eudragit(登録商標)RL 0.135
タルク 0.675
クエン酸トリエチル 0.225
Eudragit(登録商標)RS 1.215
消化管の様々状態を「シミュレートする(simulate)」かまたは模倣するために使用されることができる多くの異なる媒質が存在する。一般的に使用される主要な4種の媒質は、水、0.1N HCl、pH4.5の酢酸緩衝液、およびpH6.8のリン酸緩衝液である。これらは、中性pHについては水、酸性については絶食状態下の胃(通常、pH1〜2)、pH4.5については摂食状態下の胃(通常、pH3〜7)、pH6.8については摂食状態下の胃またはGI管の下部(即ち、小腸または大腸)のいずれかと等価である。適切な生物学的利用能を確立するために、表3に設定される種々の時点で溶解についていくらかの制限を設定した。
表4は、本発明による一般化された配合物を列挙する。B群からの全ての賦形剤が本発明による組成物中に存在する必要はないことが理解されるだろう。これらの賦形剤の1種以上が所望の放出プロフィールに依存して存在することができる。
表4
成分 %
A)
活性医薬成分 2−6
延長放出剤 〜10−50
B)
崩壊剤 1−15
結合剤 3−5
流動促進剤または流動剤 <2
充填剤 〜20−70
滑剤 〜1
合計 100
この実施例は、カプセル中に1×5mm小型タブレットを含むカプセルの本発明による特に好ましい実施形態を示す。
表5
成分 mg
ゾルピデム 1
Kollidon SR 11
Povidone K30 2
コロイドシリカ、無水物 0.5
微結晶性セルロース 35
101
ステアリン酸マグネシウム 0.5
合計 50
カプセル中に1×5mm小型タブレットを含むカプセルの本発明による、一般化された実施形態を示す。
表6
成分 mg
ロシグリタゾン 2−6
Eudragit 〜10−50
Povidone K30 3−5
コロイドシリカ、無水物 <2
微結晶性セルロース 〜20−70
101
ステアリン酸マグネシウム 〜1
合計 100
Claims (11)
- 単回投与での処置を必要とする患者への投与を可能にするように物理的に並置される1つ、2つまたは3つの別個の分離したユニットを含む制御放出配合物であって、ユニットまたは各ユニットが、未コーティングのペレットまたは小型タブレットであり、かつ
(i)8mgのガランタミンの単位投与量;
(ii)ポリビニルピロリドンとポリ酢酸ビニルの混合物であるポリマーマトリックス;
(iii)硬化植物油;
(iv)ポビドン;および
(v)ステアリン酸マグネシウム
を含み、単位投与量の合計がガランタミンの医薬的に有効な量を構成することを特徴とする制御放出配合物。 - ユニットまたは各ユニットは、1mm〜10mmの直径を有する、請求項1に記載の配合物。
- ユニットまたは各ユニットは、3mmの直径を有する、請求項2に記載の配合物。
- ユニットまたは各ユニットは、5mmの直径を有する、請求項2に記載の配合物。
- 単一のユニットがカプセル内に与えられる、請求項1〜4のいずれかに記載の配合物。
- 複数のユニットがカプセル内に与えられる、請求項1〜4のいずれかに記載の配合物。
- ユニットまたは各ユニットは、1種以上の医薬的に受容可能な賦形剤のマトリクス内に圧縮される、請求項1〜4のいずれかに記載の配合物。
- ユニット数の選択は、ガランタミンの投与量を調節することを可能にする、請求項1に記載の配合物。
- (1)ユニットまたは各ユニットが、未コーティングのペレットまたは小型タブレットであり、かつ
(i)8mgのガランタミンの単位投与量;
(ii)ポリビニルピロリドンとポリ酢酸ビニルの混合物であるポリマーマトリックス;
(iii)硬化植物油;
(iv)ポビドン;および
(v)ステアリン酸マグネシウム
を含む別個の分離したユニットを調製する工程;および
(2)単回投与における投与を可能にするように1つ、2つまたは3つの前記ユニットを物理的に並置する工程
を含むことを特徴とする、制御放出医薬組成物を調製する方法。 - ユニットは、カプセルへのユニットの導入によって物理的な並置にもたらされる、請求項9に記載の方法。
- ユニットは、タブレット内に圧縮することによって物理的な並置にもたらされる、請求項9に記載の方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2006902139 | 2006-04-26 | ||
AU2006902139A AU2006902139A0 (en) | 2006-04-26 | Extended-release formulations | |
AU2007901159A AU2007901159A0 (en) | 2007-03-07 | Modified-Release Compositions | |
AU2007901159 | 2007-03-07 | ||
PCT/AU2007/000544 WO2007121537A1 (en) | 2006-04-26 | 2007-04-26 | Controlled release formulations comprising uncoated discrete unit(s) and an extended release matrix |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2009534429A JP2009534429A (ja) | 2009-09-24 |
JP5826456B2 true JP5826456B2 (ja) | 2015-12-02 |
Family
ID=38624478
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009506867A Expired - Fee Related JP5826456B2 (ja) | 2006-04-26 | 2007-04-26 | コーティングされていない分離したユニットおよび延長放出マトリクスを含む制御放出配合物 |
Country Status (11)
Country | Link |
---|---|
US (1) | US20090169617A1 (ja) |
EP (1) | EP2010158B1 (ja) |
JP (1) | JP5826456B2 (ja) |
AU (1) | AU2007242077B2 (ja) |
CA (1) | CA2648495C (ja) |
ES (1) | ES2572180T3 (ja) |
HU (1) | HUE029173T2 (ja) |
NZ (1) | NZ703464A (ja) |
PL (1) | PL2010158T3 (ja) |
SI (1) | SI2010158T1 (ja) |
WO (1) | WO2007121537A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2190419A1 (en) * | 2007-10-05 | 2010-06-02 | KRKA, D.D., Novo Mesto | Multi particulate matrix system containing galantamine |
EP2044933A1 (en) * | 2007-10-05 | 2009-04-08 | KRKA, D.D., Novo Mesto | Multi particulate matrix system containing galantamine |
PE20141034A1 (es) | 2008-03-11 | 2014-09-10 | Takeda Pharmaceutical | Preparacion solida de desintegracion oral |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4173626A (en) | 1978-12-11 | 1979-11-06 | Merck & Co., Inc. | Sustained release indomethacin |
HU190619B (en) * | 1983-11-11 | 1986-09-29 | Bezzegh,Denes,Hu | Process for producing tablets with controlled dissolution of active ingredients |
IE60311B1 (en) * | 1987-09-24 | 1994-06-29 | American Home Prod | Sustained release etodolac |
CA1326632C (en) | 1988-10-26 | 1994-02-01 | Bonnie Davis | Long-active drug formulations comprising galanthamine for treatment of alzheimer's disease |
DE4139118A1 (de) | 1991-11-28 | 1993-06-03 | Schwabe Willmar Gmbh & Co | Retardierte mikrotablette, verfahren zu ihrer herstellung und ihre verwendung |
US5231811A (en) | 1992-03-16 | 1993-08-03 | Chicago Bridge & Iron Technical Services Company | Storage structures with layered thermal finish covering |
US5609884A (en) * | 1992-08-31 | 1997-03-11 | G. D. Searle & Co. | Controlled release naproxen sodium plus naproxen combination tablet |
DE4413350A1 (de) * | 1994-04-18 | 1995-10-19 | Basf Ag | Retard-Matrixpellets und Verfahren zu ihrer Herstellung |
PE57198A1 (es) | 1996-03-25 | 1998-10-10 | American Home Prod | Formula de liberacion prolongada |
TW506836B (en) * | 1996-06-14 | 2002-10-21 | Janssen Pharmaceutica Nv | Fast-dissolving galanthamine hydrobromide tablet |
DE69831335T3 (de) * | 1997-06-06 | 2015-01-15 | Depomed, Inc. | Im magen verweilende orale dosierungsformen von wasserlöslichen arzneistoffen mit kontrollierter freisetzung |
CA2320900C (en) | 1998-03-19 | 2009-10-27 | Bristol-Myers Squibb Company | Biphasic controlled release delivery system for high solubility pharmaceuticals and method |
US8293277B2 (en) * | 1998-10-01 | 2012-10-23 | Alkermes Pharma Ireland Limited | Controlled-release nanoparticulate compositions |
JP5558648B2 (ja) | 1998-11-23 | 2014-07-23 | デイビス、ボニー | アセチルコリンエステラーゼ阻害剤のための投与製剤 |
US7160559B1 (en) * | 1998-12-24 | 2007-01-09 | Janssen Pharmaceutica N.V. | Controlled release galantamine composition |
US6294199B1 (en) * | 1999-04-13 | 2001-09-25 | Beecham Pharmaceuticals (Pte) Limited | Method of treating a bacterial infection comprising administering amoxycillin |
EP1064937A1 (en) * | 1999-06-28 | 2001-01-03 | Sanofi-Synthelabo | Timed dual release dosage forms comprising a short acting hypnotic or a salt thereof |
US7022663B2 (en) * | 2000-02-18 | 2006-04-04 | Yeda Research And Development Co., Ltd. | Oral, nasal and pulmonary dosage formulations of copolymer 1 |
DE10015479A1 (de) * | 2000-03-29 | 2001-10-11 | Basf Ag | Feste orale Darreichungsformen mit retardierter Wirkstofffreisetzung und hoher mechanischer Stabilität |
US6761904B2 (en) | 2000-03-31 | 2004-07-13 | Nycomed Austria Gmbh | Pharmaceutical kit comprising midodrine as active drug substance |
JP2002020290A (ja) * | 2000-06-27 | 2002-01-23 | Pharmaquest Ltd | l−トレオ・メチルフェニデートを用いたうつ病を処置する方法 |
ITMI20010220A1 (it) | 2001-02-05 | 2002-08-05 | Valpharma Sa | Formulazioni multiparticolate per somministrazione orale di sali di litio idonee per una somministrazione al giorno |
AR034813A1 (es) | 2001-07-20 | 2004-03-17 | Novartis Ag | Composiciones farmaceuticas y uso de las mismas |
EP1450783A1 (en) * | 2001-10-08 | 2004-09-01 | Sun Pharmaceuticals Industries Ltd. | New anti-asthmatic drug (asmakure) from indigenous herbs to cure the disease asthma |
DE10152351B4 (de) * | 2001-10-18 | 2005-09-22 | Schering Ag | Feste Arzneimittelformulierung für ein Piperazinharnstoffderivat |
KR100540035B1 (ko) * | 2002-02-01 | 2005-12-29 | 주식회사 태평양 | 다단계 경구 약물 방출 제어 시스템 |
US6717015B2 (en) | 2002-03-28 | 2004-04-06 | Synthon Bv | Venlafaxine besylate |
WO2003099214A2 (en) * | 2002-05-23 | 2003-12-04 | Andrx Corporation | Biguanide formulations |
KR101120729B1 (ko) | 2002-10-25 | 2012-04-23 | 라보팜 인코포레이트 | 서방 조성물 |
PT1594460E (pt) * | 2002-10-25 | 2008-06-27 | Labopharm Inc | Formulações de tramadol de libertação sustentada com eficácia durante 24 horas |
US8487002B2 (en) * | 2002-10-25 | 2013-07-16 | Paladin Labs Inc. | Controlled-release compositions |
US20040097484A1 (en) * | 2002-11-14 | 2004-05-20 | Marc Cantillion | Once a day galantamine pharmaceutical compositions and methods of use |
US20050038042A1 (en) * | 2002-11-15 | 2005-02-17 | Jenet Codd | Modified release composition comprising a short-acting hypnotic for treatment of sleep disorders |
SI1502587T1 (sl) | 2003-07-30 | 2007-02-28 | Pharmathen Sa | Formulacija z zadrzevanim sproscanjem za Venlafaxin hidroklorid |
WO2005048979A2 (en) | 2003-10-06 | 2005-06-02 | Torrent Pharmaceuticals Limited | Pharmaceutical composition having casing with multiple micro tablets |
US20050191349A1 (en) * | 2003-12-31 | 2005-09-01 | Garth Boehm | Galantamine formulations |
US20050181052A1 (en) * | 2004-02-17 | 2005-08-18 | Patel Satishkumar A. | Lansoprazole microtablets |
US8007827B2 (en) * | 2004-04-02 | 2011-08-30 | Impax Laboratories, Inc. | Pharmaceutical dosage forms having immediate release and/or controlled release properties |
US20050226923A1 (en) * | 2004-04-07 | 2005-10-13 | Gassert Chad M | Venlafaxine compositions in the form of microtablets |
GB0408308D0 (en) | 2004-04-14 | 2004-05-19 | Vectura Ltd | Pharmaceutical compositions |
UA88477C2 (ru) * | 2004-08-13 | 2009-10-26 | Бёрингер Ингельхайм Интернациональ Гмбх | Композиция пеллеты пролонгированного высвобождения, которая содержит прамипексол или его фармацевтически приемлемую соль, способ ее изготовления и ее применение |
BRPI0607017B8 (pt) * | 2005-04-06 | 2021-05-25 | Adamas Pharmaceuticals Inc | composição farmacêutica compreendendo memantina e donezepil, e seu uso para o tratamento de condições relacionadas ao snc |
WO2007029081A1 (en) * | 2005-09-05 | 2007-03-15 | Ranbaxy Laboratories Limited | Galantamine-containing controlled release oral dosage forms, processes for the preparation thereof and use for the manufacture of a medicament |
-
2007
- 2007-04-26 NZ NZ703464A patent/NZ703464A/en unknown
- 2007-04-26 SI SI200731773A patent/SI2010158T1/sl unknown
- 2007-04-26 WO PCT/AU2007/000544 patent/WO2007121537A1/en active Application Filing
- 2007-04-26 HU HUE07718791A patent/HUE029173T2/hu unknown
- 2007-04-26 JP JP2009506867A patent/JP5826456B2/ja not_active Expired - Fee Related
- 2007-04-26 PL PL07718791.2T patent/PL2010158T3/pl unknown
- 2007-04-26 US US12/296,456 patent/US20090169617A1/en not_active Abandoned
- 2007-04-26 ES ES07718791T patent/ES2572180T3/es active Active
- 2007-04-26 CA CA2648495A patent/CA2648495C/en active Active
- 2007-04-26 EP EP07718791.2A patent/EP2010158B1/en not_active Revoked
- 2007-04-26 AU AU2007242077A patent/AU2007242077B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
PL2010158T3 (pl) | 2016-09-30 |
HUE029173T2 (hu) | 2017-02-28 |
ES2572180T3 (es) | 2016-05-30 |
AU2007242077A1 (en) | 2007-11-01 |
AU2007242077B2 (en) | 2013-11-14 |
EP2010158B1 (en) | 2016-02-17 |
EP2010158A4 (en) | 2012-10-03 |
CA2648495C (en) | 2016-07-05 |
SI2010158T1 (sl) | 2016-08-31 |
US20090169617A1 (en) | 2009-07-02 |
WO2007121537A1 (en) | 2007-11-01 |
EP2010158A1 (en) | 2009-01-07 |
CA2648495A1 (en) | 2007-11-01 |
NZ703464A (en) | 2016-05-27 |
JP2009534429A (ja) | 2009-09-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5905872B2 (ja) | タペンタドールの制御放出医薬組成物 | |
US8637512B2 (en) | Formulations and method of treatment | |
RU2325163C2 (ru) | Композиции с пролонгированным высвобождением, включающие ламотригин | |
US20120015031A1 (en) | Novel gastro-retentive dosage forms | |
CA2447005A1 (en) | Oral controlled release pharmaceutical composition for one-a-day therapy for the treatment and prophylaxis of cardiac and circulatory diseases | |
JP5351490B2 (ja) | ニフェジピン含有有核錠剤およびその製法 | |
US11324707B2 (en) | Abuse-deterrent dosage forms containing esketamine | |
MX2008015358A (es) | Composiciones farmaceuticas para liberacion sostenida de fenilefrina. | |
US20070122480A1 (en) | Sustained release formulations | |
KR20070069105A (ko) | 서방성 제제 | |
JP3751287B2 (ja) | 小型化されたニフェジピン有核錠剤 | |
EP1530458A1 (en) | Extended release matrix tablets | |
JP5826456B2 (ja) | コーティングされていない分離したユニットおよび延長放出マトリクスを含む制御放出配合物 | |
JP2019532960A (ja) | エソメプラゾール含有複合カプセル剤及びその製造方法 | |
US20060147530A1 (en) | Sustained release compositions containing alfuzosin | |
KR20170001545A (ko) | 모사프리드 서방성 제제 및 모사프리드와 라베프라졸의 복합제제 | |
KR20160105662A (ko) | 에페리손과 펠루비프로펜을 함유하는 약제학적 조성물 | |
US20150224056A1 (en) | Pharmaceutical compositions of ibuprofen and famotidine | |
AU2013202441B2 (en) | Controlled release formulations comprising uncoated discrete unit(s) and an extended release matrix | |
KR20050114921A (ko) | 방출제어형 약제학적 조성물 | |
US20080206338A1 (en) | Controlled release formulations of an alpha-adrenergic receptor antagonist | |
US20090202633A1 (en) | Extended release formulations of guaifenesin | |
US20130236538A1 (en) | Pharmaceutical compositions of ibuprofen and famotidine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20081027 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100422 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120703 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120913 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120921 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130104 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20130604 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131002 Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20131002 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20131126 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20140117 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140916 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140919 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150611 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150826 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20151014 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5826456 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |